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Abstract
Anthracyclines are chemotherapeutic drugs known to induce heart failure in a dose-depen-
dent manner. Mechanisms involved in anthracycline cardiotoxicity are an area of relevant
investigation. Caveolins bind, organize and regulate receptors and signaling molecules
within cell membranes. Caveolin-3 (Cav-3), integrins and related membrane repair proteins
can function as cardioprotective proteins. Expression of these proteins in anthracycline-
induced heart failure has not been evaluated. We tested the hypothesis that daunorubicin
alters cardioprotective protein expression in the heart. Rabbits were administered daunoru-
bicin (3 mg/kg, IV) weekly, for three weeks or nine weeks. Nine weeks but not three weeks
of daunorubicin resulted in progressive reduced left ventricular function. Cav-3 expression
in the heart was unchanged at three weeks of daunorubicin and increased in nine week
treated rabbits when compared to control hearts. Electron microscopy showed caveolae in
the heart were increased and mitochondrial number and size were decreased after nine
weeks of daunorubicin. Activated beta-1 (β1) integrin and the membrane repair protein
MG53 were increased after nine weeks of daunorubicin vs. controls with no change at the
three week time point. The results suggest a potential pathophysiological role for Cav3,
integrins and membrane repair in daunorubicin-induced heart failure.
Introduction
Cancer remains the second highest cause of mortality in the U.S. [1], behind heart disease.
Understanding the wide-range of side effects of cancer therapeutics including cardiotoxicity is
essential to optimize therapy and to improve disease and treatment-related survival [2].
Anthracyclines, such as daunorubicin and doxorubicin, are important components of chemo-
therapy protocols that have been used for over fifty years. Anthracyclines are among the most
potent anticancer drugs and are associated with increased patient survival [3]. However,
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clinical utility is limited by dose-dependent cardiotoxicity that adversely affects 10–30 percent
of patients [3]. The morbidity associated with anthracycline-induced cardiotoxicity requires
that serial assessment of cardiac function be performed before, during and after treatment.
The mechanisms of anthracycline-induced cardiac damage are an important area of investiga-
tion [2]. Mechanisms proposed for anthracycline-induced cardiotoxicity include oxidative
stress and free radical production, disruption of DNA and RNA synthesis, decreased progeni-
tor cell populations [2,4–6], altered autophagic flux [7], and alterations in multidrug-resistant
efflux proteins [8]. Most studies of anthracycline-induced cardiotoxicity have been conducted
in rodents [4,7,9]. There is a need for assessment of chemotherapeutics in larger animals to
provide clinically relevant data that may elucidate novel mechanisms leading to anthracycline-
induced cardiotoxicity.
Caveolae and caveolin proteins are of interest in studies of the pathogenesis of heart failure
[10–12] and have not been investigated in anthracycline-induced cardiotoxicity. Caveolae are
flask-like invaginations of the plasma membrane that are enriched in cholesterol, sphingoli-
pids, and caveolin proteins (Cav-isoforms 1, 2 and 3) [13]. Cav-3 is the predominant subtype
in striated muscle cells and is necessary for caveolae formation in cardiac myocytes [14].
Caveolae, caveolins, and their binding partners including integrins and membrane repair pro-
teins, have been linked to a range of cellular functions including oxidative stress, mitochon-
drial damage, and alterations in multidrug-resistant protein function. Expression of Cav-3 in
the heart reduces oxidative stress and preserves mitochondrial function after ischemia and
reperfusion [15]. Drug-sensitive cancer cells display up-regulation of Cav-1 and Cav-2 expres-
sion after doxorubicin exposure [16,17]. Our prior work showed that Cav-3 co-localizes with
β1D integrin in cardiac myocytes and can modify integrin function [18]. The membrane repair
protein mitsugumin-53 (MG53) forms functional complexes with Cav-3 and cavin-1. Cavin-1
is a key molecule in caveolae and membrane repair processes [19] and essential for multi-drug
resistance responses in cancer cells [8].
Here we studied anthracycline-cardiotoxicity in rabbits to expand on extensive prior
studies in small rodents. We specifically addressed the effects of daunorubicin on caveolae,
caveolins, integrins and membrane repair proteins in this clinically relevant model. We
hypothesized that Cav-3, integrins and membrane repair proteins would be altered in anthra-
cycline-induced cardiotoxicity. We showed increased myocyte caveolae number and increased
expression of Cav-3, activated β1 integrins, and the membrane repair protein MG53 in dauno-
rubicin-induced heart failure. The results suggest that alterations in caveolae and these pro-
teins may be mechanistically involved in daunorubicin -induced cardiotoxicity and therefore
warrant further study to identify new avenues to prevent or reduce the limiting side effects of a
key group of cancer therapeutics.
Materials and methods
Rabbit model of daunorubicin (Dau) cardiotoxicity
Rabbits were handled in compliance with NIH guidelines, the Guide for the Care and Use of
Laboratory Animals (National Academy of Science). Protocols were approved by the VA San
Diego Healthcare System Institutional Animal Care and Use Committee. Male and female
New Zealand White rabbits weighing [3.0 ± 0.2 kg (control, n = 8), 3.0 ± 0.1 kg (3 weeks of
Dau, n = 6), 3.2 ± 0.1 kg (9 weeks of Dau, n = 8)] were purchased from Western Oregon Rabbit
Company (Philomath, OR). Each experimental group included equal numbers of male and
female rabbits.
Daunorubicin (Dau) (MP Biomedicals, Santa Ana, CA) was administered as 3 mg/kg, i.v.,
weekly, for either three weeks (3w Dau) to evaluate early effects of Dau, or for nine weeks (9w
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Dau) to produce severe cardiotoxicity [20,21]. Echocardiography was performed in the Dau-
treated rabbits at pre-injection (time 0) and 6, 7, 8, 9, 10, 11, 12 weeks after the 1st Dau injec-
tion (9w Dau) or at pre-injection and 3 weeks after the 1st Dau injection (3w Dau). Cardiac
function of all Dau-treated rabbits was serially assessed by echocardiography and rabbits in the
nine week Dau group were killed when left ventricular (LV) fractional shortening (FS) was
reduced to<20%. Control rabbits were non-treated and sex, age and strain matched. At termi-
nation of the study, rabbits were pre-medicated with midazolam (2mg/kg) for 20 minutes and
then anesthetized with isoflurane inhalation (5%) and were heparinized with 500 U/kg of hep-
arin. Then rabbits received 10ml of KCL to arrest the hearts in diastole. Hearts were rapidly
excised, washed in PBS, and retrogradely perfused with ice-cold saline; weighed and cut into
transverse sections for further study.
Echocardiography
LV systolic function was assessed during the time course of the study using echocardiography
via a Philips SONOS 5500 echocardiographic machine with S12 probe (frequency: 5–12 MHz)
(Philips, Amsterdam, Netherlands). Rabbits were sedated with midazolam (2 mg/kg, intramus-
cular) and 1.5% isoflurane administered via inhalation. Guided M-mode imaging was per-
formed at the left ventricular papillary muscle level, and FS was calculated from LV
dimensions at end-systole (LVDS) and end-diastole (LVDD) as FS = (LVDD-LVDS)100/
LVDD. LV ejection fraction (EF) was calculated using the Teichholz method [22].
Western blot and antibodies
Immunoblotting was performed on rabbit heart protein lysates as previously described [23].
Antibodies used were: Cav-1 (3267, Cell Signaling, Danvers, MA), Cav-3 (610421, BD Biosci-
ences, San Jose, CA), DRP1 (sc-32898, Santa Cruz), mitofusin-1 (D6E2S, Cell Signaling), Opa-
1 (ab55618, Abcam), talin-1 (Serotec, Raleigh, NC), talin-2 (Serotec), α-tubulin (DHSB, Iowa
City, IA), vinculin (V 9131, Sigma, St. Louis, MO), activated β1 integrin (9EG7) (550531, BD
Biosciences) MG53 (ab83302, Abcam, Cambridge, MA), and PTRF/cavin-1 (611258, BD Bio-
sciences). Antibodies for β1A andβ1D integrin were kindly provided by Dr. Robert S. Ross
[24].
Electron microscopy
Electron microscopy was performed as previously described [15,25]. Briefly, heart tissues were
fixed with 2.5% glutaraldehyde in 0.1 mol/L cacodylate buffer for 2 hours, postfixed in 1%
OsO4 in 0.1 mol/L cacodylate buffer (1 hour), and embedded as monolayers in LX-112 (Ladd
Research, Williston, VTT). Sections were stained in uranyl acetate and lead citrate and were
observed with an electron microscope (JEOL 1200 EX-II, JEOL USA, Peabody, Mass; or Phil-
ips CM-10, Philips Electronic Instruments, Mahwah, NY). Caveolae were quantified on ran-
dom images per length of sarcomere.
Sucrose density membrane fractionation
Whole heart samples were fractionated to isolate caveolar-rich domains using a detergent-free
method as previously described [25].
Histology and immunohistochemistry
Heart tissues were transversely cut and post-fixed by immersion in 4% neutral formaldehyde
and embedded in paraffin. Serial sections (6 μm thick) were prepared by conventional
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histological processing,and stained with hematoxylin and eosin (H&E) and Masson’s blue tri-
chrome (for detection of fibrosis). Photomicrographs were imaged using a BZ-X700 micro-
scope (KEYENCE, Osaka, Japan). Fibrosis area and percentage of field were measured by
using image-J. Three fields for each rabbit were measured and the mean value of the fields was
used to represent the value for each rabbit.
Immunohistochemical analysis was performed as previously described [26]. The specimens
were incubated for 5 min in peroxidase-blocking reagent (DAKO Laboratories, Carpinteria,
CA) to inactivate endogenous peroxidases. Slides were incubated with primary antibody at
4˚C for 24 hours, and then for 30 min in biotinylated mouse anti-goat IgG, and for an addi-
tional 30 min in avidin-biotin-horseradish peroxidase complex (both from Vector, Burlin-
game, CA). The peroxidase reactivity was demonstrated with DAB+, Liquid (DAKO
Laboratories).
Cholesterol assays
Cholesterol in sucrose density fractions was measured with the Amplex Red Cholesterol Assay
Kit (Invitrogen) as described by the manufacturer.
Statistical analysis
Data are presented as mean ± SEM. Statistical analysis was performed between 2 groups using
unpaired 2-tailed Student’s t-test or unpaired t-test with Welch’s correction, and among multi-
ple groups using 1-way analysis of variance followed by Tukey’s multiple comparison test.
p<0.05 was considered significant.
Results
Daunorubicin-induced cardiotoxicity
In order to develop a model of anthracycline-induced cardiotoxicity in animals larger than
rodents, we exposed rabbits to three weeks or nine weeks of daunorubicin (Dau) exposure.
Eight of eleven rabbits survived until the end of study in the 9w Dau group and there was no
mortality in the 3w Dau group. Nine weeks of Dau treatment resulted in a progressive decline
of LV function, as measured by LVEF and LVFS (Fig 1A and Table 1). At the study termina-
tion in the nine week Dau group, not only were LVEF and LVFS significantly decreased, but
LV chamber dilation was noted when compared to the pre-Dau measurements (Table 1, Fig
1B). Mitral regurgitation (MR) was observed in all rabbits in the 9w Dau group at study end
(Fig 1C). In contrast to the 9w Dau group, the 3w Dau group showed no significant changes in
LVEF, LVFS, MR, as compared to the pre-treatment evaluation (Table 1).
At study termination we performed morphometry. Heart weight/body weight and heart
weight/tibia length were increased in the 9w Dau-treated rabbits compared to controls. No
changes in these morphometric parameters were observed in the 3w Dau group (Fig 1D and
1E). Histology of the hearts of 9w Dau-treated rabbits revealed degenerated cardiomyocytes
and vacuolization (Fig 1F). Furthermore, the 9w Dau-treated rabbits had perivascular and
interstitial cardiac fibrosis compared with control rabbits and rabbits in the 3w Dau group (Fig
1G and 1H). Thus we established a rabbit model in which the effects of Dau could be evaluated
early (3w) when cardiac function was preserved, and later (9w) when heart failure was evident.
Caveolin expression in the heart after daunorubicin
Given the potential role of caveolins in the pathogenesis of heart failure we examined the
expression of caveolin isoforms after Dau exposure. Caveolin-1 and -3 are expressed in the
Caveolins, integrins and plasma membrane repair proteins in anthracycline-induced heart failure
PLOS ONE | https://doi.org/10.1371/journal.pone.0177660 May 12, 2017 4 / 18
Fig 1. Dau-induced cardiotoxicity in vivo. (A) Ejection fraction (EF) was decreased with 9w Dau treatment. (n = 8) (B)
Representative M-mode image of echocardiography before Dau treatment (Pre) and after 3w and 9w of Dau treatment. (C)
Mitral regurgitation was found in the 9w Dau-treated rabbits. LA indicates left atrium. (D) Heart to tibia length ratios for Dau-
treated and control rabbits (n = 6–8) (E) Heart to body weight (Bw) ratios for Dau-treated and control rabbits (n = 6–8) (F)
Hematoxylin and eosin stain of LV from Dau-treated and control hearts (scale bar = 20μm) (G) Masson trichome stain of LV
from Dau-treated and control hearts. Blue indicates fibrosis. (scale bar = 50μm) (H) Quantification of (G) (n = 6–8,
respectively), *p<0.05, **p<0.01, ***p<0.001, LV, Left Ventricle; RV, Right Ventricle; LVDS and LVDD, LV dimensions in
systole and diastole.
https://doi.org/10.1371/journal.pone.0177660.g001
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heart, however the relative distribution of caveolin isoforms in the left and right ventricle (RV)
has not been assessed. We first measured Cav-1 and Cav-3 protein expression using Western
blotting of LV, intraventricular septum (IVS) and RV in control rabbits (Fig 2A and 2B).
Expression of Cav-3 was higher in the RV than in the LV or IVS. However, no difference in
Cav-1 protein expression was observed among the three regions.
Next, we examined whether Dau treatment affected the expression of Cav-1 and Cav-3 in
the heart (Fig 3A–3F). Hearts sampled after 9 weeks of Dau treatment showed increased Cav-3
expression in the LV, IVS and RV, compared to control tissues, whereas Cav-3 in 3w Dau
group was unchanged. In contrast to Cav-3, Cav-1 was not changed in any experimental
group.
We next examined the immunomicroscopic localization of Cav-3 protein within the heart.
Hearts from 9w Dau-treated rabbits had a strong immunoreaction for Cav-3 (Fig 3G). As pre-
dicted from the fact that Cav3 is expressed primarily in muscle cells, Cav-3 was localized in the
cardiac myocytes. These results suggest that when heart failure is induced by 9 weeks of Dau
treatment, Cav-3 expression is increased in the rabbit heart.
To expand our initial findings, hearts from Dau-treated and control rabbits were fraction-
ated on a discontinuous sucrose gradient and analyzed for distribution of caveolin proteins.
Cav-3 was unchanged after 3 weeks of Dau treatment and increased by 9 weeks of Dau treat-
ment in buoyant fractions (BF) (numbers 4 through 6 in the 12-step gradient) (Fig 4B and
4D). No significant difference in Cav-1 protein expression was observed in buoyant membrane
fractions at any time point (Fig 4A and 4C). Cholesterol content and protein concentration
were not changed in any of the experimental groups (Fig 4E and 4F).
Caveolae in the heart after daunorubicin
Since caveolin proteins are essential for formation of caveolae, we next evaluated caveolae for-
mation by electron microscopy. Representative electron microscopy images show that forma-
tion of caveolae were easily observed in Dau-treated and control rabbits (Fig 4G). The number
Table 1. Cardiac function in Dau-treated rabbit during echocardiography.
Pre 3w Pre 9w
HR (bpm) 271 ± 20 232 ± 12 241 ± 9 256 ± 13
IVSd (mm) 2.6 ± 0.1 2.7 ± 0.1 2.4 ± 0.1 2.9 ± 0.1*
LVDd (mm) 15.5 ± 0.5 16.7 ± 0.6 14.9 ± 0.5 18.9 ± 0.6*
LVPWd (mm) 2.8 ± 0.4 2.9 ± 0.3 2.5 ± 0.1 3.2 ± 0.2*
IVSs (mm) 3.9 ± 0.2 3.9 ± 0.3 3.6 ± 0.1 3.8 ± 0.2
LVDs (mm) 10.6 ± 0.1 11.6 ± 0.6 9.9 ± 0.3 16.1 ± 0.6*&
LVPWs (mm) 4.0 ± 0.2 4.2 ± 0.2 3.7 ± 0.3 3.9 ± 0.2
FS (%) 31.5 ± 0.5 30.6 ± 0.9 33.3 ± 0.6 14.6 ± 1.0*&
EF (%) 67.8 ± 0.7 66.6 ± 0.9 70.2 ± 0.8 37.6 ± 2.2*&
Data are mean ± SEM. HR, heart rate.
IVSd and IVSs, interventricular septal end-diastole and end-systole.
LVDd and LVDs, left ventricular end-diastolic diameter and end-systolic diameter.
LVPWd and LVPWs, LV posterior wall end-diastole and end-systole.
FS, fractional shortening. EF, ejection fraction.
*P < 0.05; Pre vs 9w,
&P < 0.05; 3w vs 9w.
https://doi.org/10.1371/journal.pone.0177660.t001
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of caveolae was increased significantly in cardiac myocytes from the rabbits in the 9w Dau
group compared with the control rabbits and rabbits in 3w Dau group (Fig 4H).
Mitochondrial number, size and protein expression in the heart after
daunorubicin
Next we determined the impact of Dau on the intracellular ultrastructure of the heart. Given
that Dau increases generation of reactive oxygen species (ROS) we focused on cardiac mito-
chondria. In the rabbit hearts, many mitochondria were found around the sarcolemma (Fig
5A). After three weeks of Dau treatment, mitochondrial size and mitochondrial number were
maintained. Both mitochondrial number and mitochondrial size were decreased after 9 weeks
of Dau treatment compared to control hearts (Fig 5B). We assessed changes in mitochondrial
fusion/fission and turnover by measuring the expression of fission (Drp1) and fusion (mitofu-
sin1 and Opa1), prohibitin proteins. Expression of prohibitin in the LV after 9 weeks of Dau
was lower than that of control hearts. No difference in mitofusin1, Drp-1 and Opa1 was
observed in the LV among the experimental groups (Fig 5C and 5D).
Fig 2. Expression of caveolin in the control heart. (A) Western Blot for caveolin-1 (Cav-1) and caveolin-3
(Cav-3) in rabbit left ventricle (LV), intraventricular septum (IVS) and right ventricle (RV). (B) Quantification of
Cav-1 and Cav-3, n = 6, respectively. **p<0.01. GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; NS,
not significant.
https://doi.org/10.1371/journal.pone.0177660.g002
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Fig 3. Expression of caveolin in the Dau-treated heart. (A) Western blot of Cav-1 and Cav-3 in control and Dau-treated left
ventricle (LV). (B) Quantification of Cav-1 and Cav-3 in the LV, n = 6, respectively. (C) Western blot of Cav-1 and Cav-3 in
control and Dau-treated intraventricular septum (IVS). (D) Quantification of Cav-1 and Cav-3 in the IVS, n = 6, respectively.
(E) Western blot of Cav-1 and Cav-3 in control and Dau-treated right ventricle (RV). (F) Quantification of Cav-1 and Cav-3 in
the RV, n = 6, respectively. (G) Representative images of immunostaining for Cav-3 in the control rabbit LV and Dau-treated
rabbit hearts. Scale bar; 20 μm *p<0.05, **p<0.01, ***p<0.001. GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; NS,
not significant.
https://doi.org/10.1371/journal.pone.0177660.g003
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Fig 4. Caveolae number in cardiac myocyte from Dau-treated and control hearts. (A-B) Excised control and Dau-
treated hearts underwent sucrose density fractionation. Fractions were probed for Caveolin-1 (Cav-1) and Caveolin-3
(Cav-3). Cav-3, but not Cav-1, was increased in BFs in 9w Dau-treated heart (representative immunoblots are shown)
and confirmed by densitometry normalized to whole tissue lysate. (C-D) Quantification of (A) and (B). n = 4, respectively
(E-F) Protein and cholesterol concentration in each fraction. n = 4, (G) 9w Dau treatment increased the number of
caveolae. Electron microscopy showed an increase in number of caveolae in 9w Dau-treated vs. control hearts. Arrow
Caveolins, integrins and plasma membrane repair proteins in anthracycline-induced heart failure
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Integrin expression in the heart after daunorubicin
In a previous study we showed that Cav-3 was involved in integrin function and activation in
cardiac myocytes [18]. We therefore investigated LV integrin expression and activation after
Dau. First, we measured active and total β1 integrin, using specific antibodies for each form
(β1A, β1D, active β1 integrin), as β1 is the dominant β subunit in cardiac myocytes (Fig 6A
and 6B). Protein expression of active β1 integrin in LV was increased after 9 weeks of Dau
treatment. Total β1A integrin (the ubiquitous β1 isoform) also was increased which reflects
cardiac remodeling. No changes in total β1D integrin (the muscle dominant β1 isoform)
expression were observed after 9 weeks of Dau when compared to control hearts and 3 weeks
of Dau treatment. We also evaluated integrin-related proteins (Fig 6A and 6B), including talin
and vinculin. There were no significant changes in talin-1, talin-2 or vinculin expression
among the experimental groups.
Membrane repair proteins in the heart after daunorubicin
Given that Dau may provoke membrane damage, we next evaluated membrane repair associ-
ated proteins. Cav-3 has been shown to be an interacting partner of MG53, which has been
implicated in membrane repair processes. We measured protein expression of MG53 in Dau-
treated hearts. After 3 weeks of Dau treatment MG53 was unchanged. After 9 weeks of Dau
treatment, MG53 in the LV was increased (Fig 7A and 7B). PTRF/cavin-1 was not significantly
different at either Dau-treated time point or between Dau-treated or control rabbits. We con-
firmed that MG53 was present in buoyant membrane fractions where Cav-3 is present (see Fig
4B) in hearts at both Dau-treated time points and in control hearts. However, the majority of
the MG53 protein was located in heavy membrane fractions (Fig 7C).
Discussion
Heart failure produced by chemotherapeutics is an increasingly important clinical concern
[2]. Extensive study of anthracycline-induced cardiotoxicity has been conducted predomi-
nantly in small rodents. We developed a reproducible model of heart failure induced by dau-
norubicin (Dau) administration in rabbits, to increase the clinical relevance and therapeutic
potential of the model. We sought to examine how caveolins, integrins and membrane repair
proteins would be affected by anthracyclines given the important interactions of these proteins
in the pathophysiology of heart failure [18,27]. To our knowledge only one previous publica-
tion has examined a role for Cav-1 and Cav-3 in anthracycline cardiotoxicity. This group
showed that Cav-1 and Cav-3 are required for doxorubicin-induced apoptosis in atrial cardio-
myocytes [28]. The expression and interaction of caveolins, integrins and membrane repair
proteins has not been addressed in anthracycline-induced heart failure. We show that heart
failure with reduced ejection fraction can be induced in rabbits with nine weeks of exposure to
Dau. Additionally, we show that expression of Cav-3, activated β1 integrins and membrane
repair proteins are increased in hearts after nine weeks of Dau treatment.
Anthracyclines are an important component of many chemotherapy protocols but utility is
limited by dose-dependent cardiotoxicity [3]. Doxorubicin and daunorubicin have similar
anticancer effects, though Dau reaches higher peak intracellular concentrations than doxoru-
bicin in leukemic cells [29]. Daunorubicin is less cardiotoxic than doxorubicin among survi-
vors of human pediatric cancer [30–32]. In rabbits, Dau produces less nephrotoxicity
indicates caveolae. Scale bar; 500 nm, (H) Caveolae number in Dau-treated and control left ventricle. (n = 10–13,
respectively) *p<0.05, **p<0.01, NS, not significant; BF, buoyant fraction; non BF, non-buoyant fraction.
https://doi.org/10.1371/journal.pone.0177660.g004
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Fig 5. Mitochondrial changes in the Dau-treated heart. (A-B) Representative electron microscopic images of LV from Dau-
treated and control hearts. Mitochondrial number and size were decreased after 9w Dau treatment when compared to
mitochondria in control rabbit hearts. Scale bar = 2 μm (n = 14–17 and n = 41–53) (C) Western Blot of mitofusin-1, Opa-1,
prohibitin and DRP-1 in LV from Dau-treated and control hearts. (D) Quantification of (C), n = 4–6, respectively. *p<0.05,
***p<0.001. LV, left ventricle; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; NS, not significant.
https://doi.org/10.1371/journal.pone.0177660.g005
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compared to doxorubicin [33]. Many previous studies of anthracycline cardiotoxicity used
doxorubicin in rodents, primarily administered via intraperitoneal injection [7]. We chose
to evaluate Dau via intravenous administration in rabbits given its favorable cardiotoxic
equivalence and reduced off target side effects when compared to doxorubicin. Further
Fig 6. Integrins and related proteins in the Dau-treated heart. (A) Western blot of active β1 integrin, β1D, β1A, talin-1, talin-2, and vinculin
in LV from Dau-treated and control hearts. (B) Quantification of (A), n = 4–6, respectively. *p <0.05, **p<0.01. GAPDH, Glyceraldehyde
3-phosphate dehydrogenase.
https://doi.org/10.1371/journal.pone.0177660.g006
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Fig 7. Membrane repair proteins in the Dau-treated heart. (A) Western blot of MG53, PTRF/cavin-1 in
rabbit left ventricle (LV) from Dau-treated and control heart. (B) Quantification of (A), n = 4–6, respectively.
Expression of MG53 in the 9w Dau-treated LV was higher than that of control LV. n = 6, respectively (C)
Whole heart protein homogenates were biochemically fractionated by sucrose gradient fractionation. MG53
was found in buoyant as well as non-buoyant fractions in LV from Dau-treated and control rabbits. *p<0.01,
NS, not significant; MG53, Mitsugumin-53; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase.
https://doi.org/10.1371/journal.pone.0177660.g007
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understanding of the pathophysiology of anthracycline-induced cardiotoxicity has potential to
produce new therapeutic options.
Currently, treatments for anthracycline-induced cardiotoxicity follow standard therapies
for congestive heart failure [34]. Having more detailed information about the mechanisms that
cause this toxicity could lead to targeted therapies. Caveolins play a major role in cardiac phys-
iology and pathophysiology [10,23,25,35,36], yet the role of caveolins in heart failure is an area
of continued research and debate. Studies have shown a wide variation in the expression levels
of caveolins and specifically Cav-3 in different heart failure models, with studies showing Cav-
3 expression being increased [37–39], decreased [11,40,41] or unchanged [42]. The reasons for
the differences in caveolin expression are not known, though variations in the species studied,
model of cardiomyopathy, and the degree and chronicity of the heart failure may play a role.
Importantly, in the present study we show for the first time that structural caveolae and Cav-3
protein are both increased after nine weeks of Dau treatment in rabbits. In contrast to our
findings, other investigators have shown that in rabbit models of pressure overload heart fail-
ure Cav-3 expression is decreased [43]. Interestingly, Cav-1 was not changed in the Dau rabbit
model we employed, despite previous findings that anthracyclines can up-regulate Cav-1
expression in cancer cells [16,17].
We also showed changes in mitochondrial size and number in the Dau-treated rabbit heart.
In highly metabolic organs like heart, mitochondria play a critical role in the adaptation to cel-
lular injury [44]. Changes in mitochondrial morphology may result in increased generation of
ROS and decreased respiratory function [15]. It is known that anthracycline-induced cardio-
toxicity involves the generation of excess ROS by electron exchange between the anthracycline
quinone moiety, oxygen molecules and other cellular electron donors [45]. ROS induces multi-
ple forms of cellular damage to cardiac myocytes, linked to excess free radical production [2].
Previously we showed that overexpressing Cav-3 in cardiac myocytes reduced generation of
ROS [15] and protected the heart from ventricular pressure overload [10], ischemia-reperfu-
sion injury [46], and ischemia-reperfusion induced apoptosis [47]. Since we have not mea-
sured ROS generation directly, the potential role for Cav-3 modulating ROS generation in
response to daunorubicin remains speculative and will require further study. We examined
two time points after exposure to Dau, three and nine weeks. At the three-week time point
heart function, mitochondrial number and size were preserved. However, at the nine-week
time point physiological and histological changes in the heart and mitochondria progressed.
In the present study, Cav-3 was unchanged after three weeks of exposure to Dau and was
increased after nine weeks of Dau treatment. The present study suggests that Cav-3 expression
and caveolae number are increased after nine weeks of Dau treatment in the rabbit heart, but
not in sufficient amounts to prevent changes in mitochondrial morphology and presumably
generation of ROS and respiratory function. Future studies should evaluate if early overexpres-
sion of Cav-3 is protective against Dau-induced cardiotoxicity.
Caveolins interact with membrane proteins including integrins and membrane repair pro-
teins. Further, caveolins can modify integrin function in cardiac myocytes [18]. We found
integrins were activated in the nine week Dau treated hearts, which may indicate a protective
mechanism that the myocyte uses to adhere more firmly to matrix in the face of stress. Plasma
membrane repair is critical for cellular homeostasis and prevention of cell death in the heart
[19]. MG53 is a muscle-specific TRIM-family protein (TRIM72) that forms a functional com-
plex with Cav-3 in the heart and contributes to intracellular vesicle trafficking and myogenesis
[27]. Polymerase-1 and transcriptase release factor (PTRF)/cavin-1 also is a key molecule in
plasma membrane repair [19]. PTRF/cavin-1 is essential for multi-drug resistance responses in
cancer cells [8]. MG53 participates in the cardioprotection associated with ischemic postcondi-
tioning through tethering Cav-3 and phosphoinositide 3-kinase (PI3K) and activation of the
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reperfusion injury salvage kinase pathway [27,48]. A recent report also showed that MG53 was
an effective biomarker of myocardial injury and dysfunction in rodent models. However in
that study, MG53 expression in the human heart was low suggesting that the role of MG53 as a
clinical biomarker of myocardial injury will require further investigation [49]. Despite evi-
dence for clear interactions between caveolins, integrins and membrane repair proteins there
are no prior studies that have linked the effects of anthracyclines to all these membrane struc-
tural proteins. Our results imply that up-regulation of Cav-3, activated integrins, and MG53 in
our Dau-induced cardiotoxicity model may reflect the critical need for membrane repair pro-
cesses when anthracycline-induced membrane injury occurs. Future work is warranted to
delineate the role of these associated proteins and membrane repair in general in anthracy-
cline-induced cardiotoxicity.
In summary, we have described the cardiac consequences of short and longer- term anthra-
cycline exposure and ultimately anthracycline-induced cardiotoxicity in rabbits. Our results
suggest a new mechanistic paradigm for anthracycline-induced cardiotoxicity involving mem-
brane-associated proteins such as caveolins, integrins and proteins involved in membrane
repair. These data add to the understanding of the pathophysiology of anthracycline-induced
cardiotoxicity and could lead to the development of novel future therapies.
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